سعر هيكسازيم حقنة مملوءة مسبقا 0.5 مل 2025

Hexavalent combined vaccine (DTaP-HepB-IPV-Hib), 0.5 ml suspension for intramuscular injection in a pre-filled syringe (Sanofi Pasteur); adsorbed on aluminium hydroxide.

• Primary and booster vaccination of infants and toddlers from six weeks of age against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b.Population: Infants and toddlers from 6 weeks of ageEuropean Medicines Agency (EMA)

• Very common: injection-site pain, erythema and swelling, irritability, crying, somnolence, decreased appetite, vomiting and fever ≥38.0 °C. Common: abnormal (prolonged) crying, diarrhoea, injection-site induration.International label, same product · European Medicines Agency (EMA)
• Uncommon: hypersensitivity, injection-site nodule, fever ≥39.6 °C. Rare: anaphylactic reaction, convulsions with or without fever, rash, extensive limb swelling. Very rare: hypotonic-hyporesponsive episodes.International label, same product · European Medicines Agency (EMA)

• Hypersensitivity to the active substances, any excipient, any pertussis vaccine, or after previous administration of this vaccine or a vaccine with the same components.International label, same product · European Medicines Agency (EMA)
• Encephalopathy of unknown aetiology within 7 days after a previous pertussis-containing vaccine; pertussis vaccination should then be discontinued and the course continued with diphtheria-tetanus, hepatitis B, polio and Hib vaccines.International label, same product · European Medicines Agency (EMA)
• Uncontrolled neurological disorder or uncontrolled epilepsy: pertussis vaccine should not be given until treatment is established and the condition has stabilised. Vaccination should be postponed in moderate or severe febrile and/or acute illness (minor infection or low-grade fever is not a contraindication).International label, same product · European Medicines Agency (EMA)

• If temperature ≥40 °C, a hypotonic-hyporesponsive episode or persistent inconsolable crying ≥3 hours within 48 hours, or convulsions within 3 days, followed a pertussis-containing vaccine, further pertussis-containing doses should be carefully considered.International label, same product · European Medicines Agency (EMA)
• Appropriate medical treatment must be available for anaphylaxis; each dose may contain traces of glutaraldehyde, formaldehyde, neomycin, streptomycin and polymyxin B. Give with caution in thrombocytopenia or bleeding disorders.International label, same product · European Medicines Agency (EMA)
• Consider the risk of apnoea and the need for 48-72 hours of respiratory monitoring when giving the primary series to very premature infants (≤28 weeks of gestation); vaccination should not be withheld or delayed.International label, same product · European Medicines Agency (EMA)

• Pneumococcal conjugate, MMR, rotavirus, meningococcal C or ACWY conjugate vaccinesMay be given at the same time (separate injection sites); no clinically relevant interference in antibody responses was shown.European Medicines Agency (EMA)
• Varicella vaccinePossible clinically relevant interference in antibody responses; should not be given at the same time.European Medicines Agency (EMA)
• Immunosuppressive therapyMay reduce the immune response to the vaccine; postponing vaccination until the end of treatment is recommended.European Medicines Agency (EMA)

• Not applicable: this vaccine is not intended for administration to women of child-bearing age.International label, same product · European Medicines Agency (EMA)